Madrigal Pharmaceuticals Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $34.5M | $8.2M |
| Jun 2017 | — | $61.6M | $34.8M |
| Sep 2017 | — | $54.3M | $13.0M |
| Dec 2017 | — | $182.3M | $148.6M |
| Mar 2018 | — | $177.2M | $38.1M |
| Jun 2018 | — | $486.1M | $264.9M |
| Sep 2018 | — | $482.9M | $38.0M |
| Dec 2018 | — | $477.0M | $57.4M |
| Mar 2019 | — | $468.5M | $47.5M |
| Jun 2019 | — | $457.0M | $72.5M |
| Sep 2019 | — | $440.3M | $89.5M |
| Dec 2019 | — | $416.6M | $46.7M |
| Mar 2020 | — | $385.5M | $66.7M |
| Jun 2020 | — | $342.9M | $61.9M |
| Sep 2020 | — | $289.7M | $109.1M |
| Dec 2020 | — | $240.0M | $54.0M |
| Mar 2021 | — | $260.6M | $44.2M |
| Jun 2021 | — | $270.7M | $33.5M |
| Sep 2021 | — | $234.9M | $49.2M |
| Dec 2021 | $0 | $196.1M | $36.3M |
| Mar 2022 | — | $145.7M | $42.3M |
| Jun 2022 | $48.7M | $83.5M | $53.3M |
| Sep 2022 | $49.0M | $10.7M | $59.3M |
| Dec 2022 | $49.3M | $197.4M | $331.5M |
| Mar 2023 | $84.0M | $150.1M | $113.3M |
| Jun 2023 | $99.2M | $103.5M | $77.2M |
| Sep 2023 | $114.7M | $22.2M | $62.1M |
| Dec 2023 | $115.5M | $405.3M | $99.9M |
| Mar 2024 | $116.1M | $850.8M | $622.5M |
| Jun 2024 | $116.6M | $857.1M | $494.6M |
| Sep 2024 | $117.1M | $777.2M | $232.7M |
| Dec 2024 | $117.6M | $754.4M | $100.0M |
| Mar 2025 | $118.0M | $710.6M | $183.6M |
| Jun 2025 | $118.4M | $696.0M | $186.2M |
| Sep 2025 | $339.8M | $625.7M | $295.7M |
| Dec 2025 | $339.9M | $602.7M | $198.7M |
| Mar 2026 | $340.3M | $543.5M | $227.0M |
| Jun 2026 | $340.8M | $523.7M | $292.7M |